Abstract:Abstract Background: Lung cancer is the leading cause of cancer death. More than half of the patients are diagnosed in the advanced stage for which the 5-year survival is below 10%. Lung cancer screening using low-dose CT scan reduced lung cancer mortality among heavy smokers. However, no standard screening method exists for non-smokers. Up to 35% and 90% of male and female lung cancer patients in Southeast Asia, respectively, do not smoke. Half of NSCLC patients in this region harbor EGFR mutations, which is common in women and non-smokers. Thus, we sought to explore novel biomarkers that help to identify lung cancer patients and those who have EGFR mutation. Metabolic reprogramming is one of the hallmarks of cancer. It leads to changes in metabolite levels in the blood. Hence, we conducted plasma metabolomic analysis to identify potential metabolite biomarkers in lung cancer patients. Methods: Plasma samples were collected from 69 lung cancer patients at Siriraj hospital and 10 healthy individuals during 2018-2022. Plasma metabolites from 29 treatment-naïve EGFR-mutated NSCLC patients, 30 treatment-naïve EGFR-wild-type NSCLC patients, 10 treatment-resistant EGFR T790M-mutated NSCLC patients, and 10 healthy individuals were profiled using GC-MS and untargeted LC-MS with Metlin database matching. EGFR mutation was detected from plasma ctDNA using real-time PCR. Negative plasma EGFR mutation results were confirmed with corresponding tumor tissues. Metabolomics data were processed by the metabox R package. Results: Among 114 candidate metabolites that passed the variable importance in projection (VIP) cutoff of 1.5, the top ten metabolites that differentiate NSCLC patients with EGFR mutation from those without were shown in Table 1. Many of them can also separate between NSCLC patients and healthy individuals. Table 1. ROC curve analysis Discriminant metabolites (Mutated EGFR vs Wild-type EGFR NSCLC) AUC Accuracy Sensitivity Specificity PG(a-13:0/i-12:0) 0.8000 0.7833 0.8333 0.7333 Nervonic ceramide 0.7736 0.6772 0.7259 0.6333 Valine 0.7678 0.7298 0.7259 0.7333 L-Histidinol 0.7644 0.7281 0.7222 0.7333 Leucine 0.7563 0.7632 0.7259 0.8000 Tryptophan 0.7425 0.6289 0.5593 0.7000 8-methylcaffeine 0.6793 0.6096 0.6222 0.6000 Formic acid 0.6759 0.6447 0.5889 0.7000 PC(20:0/24:0) 0.6506 0.6614 0.8259 0.5000 Sucrose 0.6471 0.6596 0.7593 0.5667 Discriminant metabolites (NSCLC patients vs Healthy individuals) AUC Accuracy Sensitivity Specificity Tryptophan 0.9986 0.9867 1.0000 0.9848 PC(20:0/24:0) 0.8609 0.9505 0.6111 1.0000 L-Histidinol 0.8572 0.9625 0.7778 0.9861 Formic acid 0.6696 0.9262 0.6667 0.9704 Conclusions: Plasma L-Histidinol, tryptophan, PC(20:0/24:0), and formic acid are potential metabolite biomarkers for NSCLC patients harboring EGFR mutation. Citation Format: Lucksamon Thamlikitkul, Siriphan Manocheewa, Suphitcha Limjiasahapong, Kwanjeera Wanichthanarak, Atikorn Panya, Naravat Poungvarin, Yotsawat Pomyen, Sakda Khoomrung. Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1068.

Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

Epidermal Growth Factor Receptor Mutations In Plasma Dna Samples Predict Tumor Response In Chinese Patients With Stages Iiib To Iv Non-Small-Cell Lung Cancer

Serum exosomal microRNAs as predictive markers for EGFR mutations in non–small‐cell lung cancer

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Diagnostic Value Of Mutation-Specific Antibodies For Immunohistochemical Detection Of Epidermal Growth Factor Receptor Mutations In Non-Small Cell Lung Cancer: A Meta-Analysis

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI

Low Correspondence of Egfr Mutations in Tumor Tissue and Paired Serum of Non-Small-Cell Lung Cancer Patients

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.

A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer

Abstract 1068: Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)

Analysis of Egfr Mutation Status in Tissue and Plasma for Predicting Response to Egfr-Tkis in Advanced Non-Small-Cell Lung Cancer

Impact of Plasma EGFR Mutation Fractions on Response to First Generation Tyrosine-Kinase Inhibitor in Treatment of Naïve Non-Small Cell Lung Cancer Patients

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Predicting Significance of EGFR Mutation Existing in Tissues and Plasma Concuurrently or Alone to EGFR–tyrosine Kinase Inhibitors (Egfr-Tkis) for Advanced Non-Small Cell Lung Cancer.